Drug intelligence / Profile preview

ribupatide

Development stage: Phase 3
Lead developer: Kailera Therapeutics
Modality: Peptides
Administration: Subcutaneous, Oral

Overview

Ribupatide is a dual agonist of the glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors. It is a peptide-based therapeutic being developed for the treatment of obesity, type 2 diabetes, and obstructive sleep apnea. The drug is designed to provide potent weight loss and glycemic control by mimicking the action of natural incretin hormones. It is currently being evaluated in both a once-weekly subcutaneous injectable formulation (Phase 3) and a once-daily oral formulation (Phase 2). Kailera Therapeutics holds the rights for development and commercialization outside of Greater China, while Hengrui Pharma retains the rights within Greater China.

Other names: HRS9531HRS-9531HRS 9531

Targets

GLP1R (GLP-1R)GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on ribupatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ribupatide.

Explore the full profile